Benjamin F. Edwards & Company, Inc. Immuno Gen, Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$3.45 - $4.89 $327 - $464	-95 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $315 - $507	95 New	95 $0
Q4 2019 Feb 06, 2020	SELL	$2.25 - $5.8 $4,486 - $11,565	-1,994 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$2.22 - $3.39 $4,426 - $6,759	1,994 New	1,994 $5,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.